Skip to main content
. 2010 Jan 14;25(10):2035–2048. doi: 10.1007/s00467-009-1386-4

Fig. 3.

Fig. 3

Outcomes of cardiac transplant recipients followed for >2 years. Patients were divided into those who had persistent demonstration of antiendothelial cell antibody (AECA+) posttransplant vs patients who never demonstrated positivity (AECA−) posttransplant. The importance of non-human leukocyte antigen (non-HLA) antibodies directed at endothelial cell targets not present on lymphocytes can cause antibody-mediated rejection (AMR) and graft loss [25]